Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart

Pharmacology

Volumn 56, Issue 1, 1998, Pages 30-36

  Willette, Robert N ^a   Mitchell, Marcus P ^a   Ohlstein, Eliot H ^a   Lukas, Mary Ann ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bucindolol; Carvedilol; Intrinsic sympathomimetic activity

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUCINDOLOL; CARVEDILOL; ISOPRENALINE; PROPRANOLOL;

ANIMAL EXPERIMENT; ARTICLE; CHRONOTROPISM; DOSE RESPONSE; DRUG INHIBITION; HEART RATE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; DECEREBRATE STATE; DRUG EVALUATION, PRECLINICAL; EVALUATION STUDIES; HEART FAILURE, CONGESTIVE; MALE; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHOMIMETICS;

EID: 0031963068     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028179     Document Type: Article

References (22)

1. Doughty RN, Sharpe N: Beat-adrenergic blocking agents in the treatment of congestive heart failure: Mechanism and clinical results. Annu Rev Med 1997;48:103-114.
2. Hash TW, Prisant LM: Beta-blocker use in systolic heart failure and dialated cardiomyopathy. J Clin Pharmacol 1997;37:7-19.
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334: 1349-1397.
4. The BEST Steering Committee: Design of the beta-blocker evaluation survival trial (BEST). Am J Cardiol 1995;75:1220-1223.
5. Panfilov V, Wahlquist I, Olsson G: Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drugs Ther 1995;9:273-287.
6. Northcote R: The clinical significance of intrinsic sympathomimetic activity. Int J Cardiol 1987;15:133-150.
7. Persson H, Rythe'n-Alder E, Melcher A, Erhardt L: Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: Double blind comparison of metoprolol and xamoterol. Br Heart J 1995;74:140-148.
8. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990; 336:1-6.
9. Imai Y, Watanabe N, Hahimoto J, Nishiyama A, Sakuma H, Sekino H, Omata K, Abe K: Muscle cramps and elevated creatinine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol 1995;48:29-34.
10. Packer M: Modulation of functional capacity and survival in congestive heart failure. Postgrad Med 1988; 83(suppl):96-103.
11. Soriano JB, Hoes AW, Meems L, Grobbee DE: Increased survival with beta-blockers: Importance of ancillary properties. Prog Cardiovasc Dis 1997;39:445-456.
12. Willette RN, Sauermelch CF, Hieble JP: Role of alpha-1 and alpha-2 adrenoceptors in the sympathetic control of the proximal urethra. J Pharmacol Exp Ther 1990;252:706-710.
13. Hicks PE, Cavero I, Manoury P, Lefevre-Borg F, Langer SZ: Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Exp Ther 1987;242:1025-1034.
14. Louis WJ, Drummer OH, Tung LH: Pharmacology of celiprolol. Cardiovasc Drugs Ther 1990;4:1281-1286.
15. Deitchman D, Perhach JL, Snyder RW: Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharmacol 1980;61:263-277.
16. Hershberger RE, Wynn JR, Sundberg L, Bristow MR: Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-967.
17. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR: Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(suppl B):8-16.
18. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Muller-Beckman B: Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992:19(suppl 1): S68-S80.
19. Bristow MR, Larrabee P, Muller-Beckman B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD: Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992; 70:S105-S113.
20. Dickinson KEJ, Nahorski RR: Agonist binding to mammalian beta-1 and beta-2 adrenoceptors: Modulation by guanine nucleotide and magnesium. J Recept Res 1983;3:123-135.
21. Strein K, Sponer G, Muller-Beckmann B, Bartsch W: Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties. J Cardiovasc Pharmacol 1987;10(suppl 11):S33-S41.
22. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR: In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989;39:327-336.